Huttunen 1995.

Methods	Allocation: randomised (no further description). Blindness: double (no further description). Duration: 6 weeks. Consent: given. Setting: multicentre.
Participants	Diagnosis: schizophrenia (DSM‐III‐R). N=98. Sex: 47M, 51F. Age: 11‐43 years, mean ˜ 36 years. History: chronic, currently acutely ill.
Interventions	1. Risperidone: 2‐20 mg/day, dose decided by clincial judgement. N=48. 2. Zuclopenthixol: 10‐100mg/day, dose decided by clincial judgement. N=50.
Outcomes	Clinical improvement: 20% reduction in PANSS. Comparison with previous medication: Categorical scale. Adverse effects: use of antiparkinson medication, other various observed effects. Leaving the study early. Unable to use ‐ Global effect: CGI (no SD). Mental state: PANSS, BPRS ‐ PANSS derived (no SD). Physiological monitoring: ECG, lab tests (no data). Adverse effects: ESRS, UKU (no SD).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear